Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Efficacy and safety of the combination of paclitaxel, cisplatin and bevacizumab for the treatment of non-small cell lung cancer

Hui Zhang¹, Lei Fu² , Jingwen Jiang¹, Fangfang Fu¹, Aiying Chen¹, Hui Gong³, Fengting Zhu¹

¹Department of Oncology, Hainan Hospital of Traditional Chinese Medicine, Changsha, Hu’nan Province, China; ²Departments of Dermatology, Hainan Hospital of Traditional Chinese Medicine, Changsha, Hu’nan Province, China; ³Department of Medical Oncology, Hu’nan Academy of Traditional Chinese Medicine Affiliated Hospital, Changsha, Hu’nan Province, China.

For correspondence:- Lei Fu Email: 326655171@qq.com

Accepted: 27 March 2024 Published: 30 April 2024

Citation: Zhang H, Fu L, Jiang J, Fu F, Chen A, Gong H, et al. Efficacy and safety of the combination of paclitaxel, cisplatin and bevacizumab for the treatment of non-small cell lung cancer. Trop J Pharm Res 2024; 23(4):769-775 doi: 10.4314/tjpr.v23i4.13

© 2024 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the efficacy and safety of the combined use of paclitaxel, cisplatin, and bevacizumab for the treatment of non-small cell lung cancer (NSCLC).

Methods: 98 NSCLC patients who received therapy at Hainan Hospital of Traditional Chinese Medicine, Changsha, China from January 2018 to December 2022 were retrospectively analyzed. The 45 patients who received paclitaxel and cisplatin injections were enrolled in a control group while 53 patients who received additional chemotherapy with bevacizumab injection were enrolled in a study group. Levels of vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) were compared before and after treatment. Furthermore, the efficacy and incidence of adverse reactions were evaluated and compared between the two groups.

Results: There was no significant inter-group difference in VEGF and bFGF levels (p > 0.05) before treatment. There was a significant reduction in VEGF and bFGF levels in the study group compared to control group (p < 0.05). The study group showed a significantly higher total remission rate compared to control group (p < 0.05). Furthermore, there was no significant difference in the incidence of adverse reactions between the two groups (p > 0.05). Also, age, tumor, node, metastasis (TNM) stage, metastasis, and smoking history are risk factors that influence patient prognosis.

Conclusion: Combination of paclitaxel, cisplatin and bevacizumab demonstrates significant efficacy in the treatment of NSCLC. The combination lowers VEGF and bFGF levels without worsening adverse reactions. Future large population studies would be required to obtain a more detailed and comprehensive outcome on this combination in NSCLC.

Keywords: Paclitaxel, Cisplatin, Bevacizumab, Non-small cell lung cancer, VEGF, bFGF